Endocrine Cancer News
Thyroid cancer patients who perceive no choice about radioactive iodine report lower decision satisfaction.
Treatment with once-weekly exenatide 2 mg does not increase serum calcitonin concentrations or the risk for medullary thyroid carcinoma.
Patients who initially received negative thyroid biopsy results might face higher cumulative risk of developing thyroid cancer than that projected in previous literature.
Proactive management of toxicities will be key for optimization of therapy.
In the DART study, no patients with low-grade neuroendocrine tumors achieved a response to the combination of nivolumab plus ipilimumab.
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Molecular testing may identify benign disease in some patients with thyroid nodules classified as suspicious for malignancy, helping them avoid unnecessary treatment.
Adherence to the 2015 recommendation from ATA — to use lobectomy rather than complete thyroidectomy for low-risk differentiated thyroid cancer — is increasing.
Childhood radiation-induced thyroid cancer does not affect all-cause mortality compared with healthy individuals.
RET inhibitor LOXO-292 was well tolerated and demonstrated high antitumor activity against RET-altered thyroid cancers.
Malignancy was more common in children with thyroid nodules classified as indeterminate by BSRTC criteria compared with adults.
Immune-related gene sets, including those for PD-L1/L2, are upregulated in ATC and PTC, but not in poorly differentiated disease or normal tissue.
The addition of selumetinib to radioactive iodine did not improve the complete remission rate among patients with high-risk nonmetastatic differentiated thyroid cancer.
High serum soluble PD-L1 levels are associated with shorter disease-free survival among patients with papillary thyroid cancer.
Ethanol sensitization before radiofrequency ablation of benign thyroid nodules reduced time, ablation energy, and complications compared with conventional ablation.
Outcomes after radioiodine therapy are similar after preparation with either recombinant human thyrotropin or thyroid hormone withdrawal.
Postoperative radioiodine remnant ablation did not improve long-term outcomes among patients with low-risk papillary thyroid carcinoma.
Most imaging centers in the United States fail to analyze lateral neck lymph nodes during preoperative ultrasounds in patients with thyroid cancer.
The BABA robotic thyroidectomy technique appears to be safe, with excellent outcomes in benign and malignant thyroid disease.
Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.
The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.
Pembrolizumab plus chemoradiotherapy failed to improve survival and lead to unexpected deaths in a small study of patients with anaplastic thyroid cancer.
Thyroid-based immune-related adverse events are common among patients treated with PD-L1 inhibitors.
The TRK inhibitor larotrectinib was effective and well tolerated among patients with relapsed/refractory advanced TRK-fusion thyroid cancer.
Tumor suppressor and driver genes are frequently mutated in Korean patients with anaplastic thyroid cancer.